The Association of Leukocytosis, Thrombocytosis and JAK2V617F Mutation with Thrombotic Events in Myeloproliferative Disorders (MPD's)

被引：0
|
作者：
Kundranda, Madappa N. [1 ]
Maiti, Baidehi
Iqbal, Nouman
Muslimani, Alaa A. [1 ]
Chaudhry, Asif [1 ]
Spiro, Timothy M. D. [1 ]
Daw, Hamed [1 ]
机构：
[1] Fairview Hosp, Cleveland Clin, Ctr Canc, Cleveland, OH USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：968 / 968
页数：1
相关论文
共 50 条
  • [31] The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms
    Holmstrom, M. O.
    Hjortso, M. D.
    Ahmad, S. M.
    Met, O.
    Martinenaite, E.
    Riley, C.
    Straten, P.
    Svane, I. M.
    Hasselbalch, H. C.
    Andersen, M. H.
    LEUKEMIA, 2017, 31 (02) : 495 - 498
  • [32] The JAK2V617F mutation and thrombosis
    Austin, S. K.
    Lambert, J. R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 143 (03) : 307 - 320
  • [33] The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms
    M O Holmström
    M D Hjortsø
    S M Ahmad
    Ö Met
    E Martinenaite
    C Riley
    P Straten
    I M Svane
    H C Hasselbalch
    M H Andersen
    Leukemia, 2017, 31 : 495 - 498
  • [34] Association between JAK2V617F mutation and thrombotic complication in patients with classical Ph-negative chronic myeloproliferative diseases
    Aleksandrova, T. N.
    Mulina, I. I.
    Kurtanov, K. A.
    Soloveva, I. E.
    Terekhova, L. D.
    Pavlova, N., I
    Yadrikinskaya, V. N.
    Soloveva, N. A.
    Dyakonova, A. T.
    YAKUT MEDICAL JOURNAL, 2020, (01): : 21 - 23
  • [35] JAK2 V617F mutation and the myeloproliferative disorders
    Vainchenker, William
    Casadevall, Nicole
    HEMATOLOGIE, 2006, 12 (01): : 3 - 7
  • [36] The V617F JAK2 mutation and the myeloproliferative disorders
    Percy, MJ
    McMullin, MF
    HEMATOLOGICAL ONCOLOGY, 2005, 23 (3-4) : 91 - 93
  • [37] Clinical and laboratory parameters of JAK2V617F mutation in essential thrombocytosis patients
    Koyuncuoglu, A. Altun
    Bankir, M.
    Saler, T.
    Koluman, B. Unver
    Acik, D. Yanardag
    LEUKEMIA RESEARCH, 2018, 73 : S47 - S47
  • [38] Jak2V617F Reversible Activation Shows an Essential Requirement for Jak2V617F in Myeloproliferative Neoplasms (MPNs)
    Dunbar, Andrew
    Bowman, Robert L.
    Park, Young
    Izzo, Franco
    Myers, Robert M.
    Karzai, Abdul
    Kim, Won Jun
    Maestre, Ines Fernandez
    Waarts, Michael R.
    Nazir, Abbas
    Xiao, Wenbin
    Brodsky, Max
    Farina, Mirko
    Cai, Louise
    Cai, Sheng F.
    Wang, Benjamin
    An, Wenbin
    Yang, Julie
    Mowla, Shoron
    Eisman, Shira E.
    Mishra, Tanmay
    Houston, Remie
    Guzzardi, Emily
    Benitez, Anthony R. Martinez
    Viny, Aaron D.
    Koche, Richard
    Landau, Dan A.
    Levine, Ross L.
    BLOOD, 2022, 140
  • [39] Comparison of JAK2V617F prevalence in African American and caucasian patients with myeloproliferative disease (MPD)
    Mobarek, D. A.
    Ascensao, J. L.
    Stroncek, D.
    Bennett, M.
    Adams, S.
    Kvanli, M.
    Schechter, G. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [40] ARE AGE AND JAK2V617F MUTATION RELATED TO THROMBOSIS IN CHRONIC MYELOPROLIFERATIVE DISEASES?
    Ataca, P.
    Atilla, E.
    Bozdag, S. C.
    Toprak, S. K.
    Yuksel, M. K.
    Topcuoglu, P.
    Akan, H.
    Arslan, O.
    Ozcan, M.
    Beksac, M.
    Gurman, G.
    Ilhan, O.
    THROMBOSIS RESEARCH, 2016, 141 : S33 - S33
12345